



ASX Announcement

12 February 2020

Issue of Unquoted Securities

Creso Pharma Limited (ASX:CPH, FRA:1X8) ('Creso Pharma' or 'the Company') advised that, in accordance with the Appendix 3B released to the ASX on 11 February 2020, the Company has completed the issue of the following securities:

- 3,611,112 Tranche 1 Convertible Notes, each with a face value of \$1.00;
- 575,000 Tranche 2 Convertible Notes, each with a face value of \$1.00;
- 2,128,387 Adviser Options, which are exercisable at \$0.35 each on or before 12 February 2023; and
- 6,847,725 Convertible Notes Options, which are exercisable at \$0.40 each on or before 12 February 2023.

The above securities will not be quoted. For further information on the above securities, please refer to the Prospectus dated 7 February 2020 as supplemented by the Supplementary Prospectus dated 10 February 2020.

Following the above issues of securities, the Company's issued capital is as follows:

Type of Securities	Total Number of Securities
Shares	
CPH Ordinary Fully Paid Shares	201,420,479
Options	
CPHO Listed Options (\$0.80, 21/08/2020)	72,796,411
CPHOPT2 Options (\$0.40, 27/06/2020)	400,000
CPHOPT3 Options (\$0.20, 13/10/2020)*	2,886,250
CPHOPT5 Options (\$0.50, 23/01/2021)	300,000
CPHOPT12 Options (\$0.60, 27/07/2020)	100,000
CPHOPT14 Options (\$0.80, 13/07/2021)*	150,000
CPHOPT16 Options (\$0.535, 27/07/2021)	200,000
CPHOPT17 Options (\$0.80, 27/07/2022)	200,000
CPHOPT18 Options (\$0.55, 21/08/2021)	200,000
CPHOPT19 Options (\$0.80, 15/09/2022)*	400,000
CPHOPT20 Options (\$0.35, 12/02/2023)	2,128,387
CPHOPT21 Options (\$0.40, 12/02/2023)	6,847,725



Type of Securities	Total Number of Securities
<u>Performance Shares</u>	
CPHPERSB Performance Shares*	303,027
CPHPERSC Performance Shares*	303,027
CPHPERSD Performance Shares*	303,027
CPHPERSE Performance Shares*	303,039
<u>Performance Rights</u>	
CPHPERR6 Performance Rights (T1)*	800,000
CPHPERR7 Performance Rights (T2)*	800,000
CPHPERR16 Performance Rights (T17)*	100,000
<u>Employee Performance Rights (Under Plan)</u>	
CPHPERR22 Employee Performance Rights	66,000
CPHPERR23 Employee Performance Rights	66,000
CPHPERR24 Employee Performance Rights*	132,000
CPHPERR29 Employee Performance Rights*	300,000
CPHPERR32 Employee Performance Rights*	100,000
<u>Convertible Notes</u>	
CPHCON1 Tranche 1 Convertible Notes	3,611,112
CPHCON2 Tranche 2 Convertible Notes	575,000

*Subject to performance milestones and/or vesting conditions.

*There are also 8,300,000 exchangeable shares on issue in the Company's Nova Scotia subsidiary which may be exchanged for Shares in accordance with agreed ratios subject to satisfaction of milestones and conversion by the holders.

Ends

Authority and Contact Details

This announcement has been authorised for release by Dr Miri Halperin Wernli, CEO and Managing Director of Creso Pharma Limited.

For further information, please contact:

Investor Enquiries

EverBlu Capital
E: info@everblucapital.com
P: +61 2 8249 0000

Media Enquiries

Julia Maguire | The Capital Network
E: julia@thecapitalnetwork.com.au
P: +61 419 815 38



About Creso Pharma

Creso Pharma Limited (ASX:CPH) brings the best of cannabis to better the lives of people and animals. It brings pharmaceutical expertise and methodological rigor to the cannabis world and strives for the highest quality in its products. It develops cannabis and hemp derived therapeutic, nutraceutical, and life style products with wide patient and consumer reach for human and animal health. Creso Pharma uses GMP (Good Manufacturing Practice) development and manufacturing standards for its products as a reference of quality excellence with initial product registrations in Switzerland. It has worldwide rights for a number of unique and proprietary innovative delivery technologies which enhance the bioavailability and absorption of cannabinoids. To learn more please visit: www.cresopharma.com